MedDataX Logo

PRP Intrauterine Infusion in Thawed Embryo Cycles

NCT ID: NCT03734042

Last Updated: 2021-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-01

Study Completion Date

2021-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

All patients prepared to thawed embryo transfer were classified into 2 groups one group will receive platelet rich plasma (PRP) infusion intrauterine and the other group will not receive platelet rich plasma (PRP) infusion

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients candidates for Thawed embryo transfer with Repeated implantation failure were recruited from 3 centers and classified into 2 groups:

Group I: Will receive platelet rich plasma (PRP) intrauterine infusion at day 11

Group II: Not receiving platelet rich plasma (PRP)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Evaluations

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Platelet rich plasma Intrauterine infusion Thawed embryos IVF/ICSI cycles

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

2 groups parallel
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRP group

These patients will receive platelet rich plasma intrauterine infusion at day 11

Group Type EXPERIMENTAL

Platelet rich plasma intrauterine infusion

Intervention Type BIOLOGICAL

platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11

Control group

These patients will receive intrauterine normal saline infusion at day 11

Group Type PLACEBO_COMPARATOR

Normal saline

Intervention Type BIOLOGICAL

Intrauterine infusion of normal saline at day 11

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Platelet rich plasma intrauterine infusion

platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11

Intervention Type BIOLOGICAL

Normal saline

Intrauterine infusion of normal saline at day 11

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients age 20-35 years
* Patients with previous implantation failure
* Patients with thin endometrium\<7 mm

Exclusion Criteria

* Patients older than 40 years
* Patients with fresh embryo transfer
* Patients with abnormal uterine cavity septate, or bicornuate uterus
* Patients with abnormal male factor or tubal factor
* Patients with abnormal embryos grade B or C.
* Patients with immunological disorders as thyroidits or systemic lupus or rheumatoid arthritis
Minimum Eligible Age

20 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ayman S Dawood, MD

Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ayman Shehata Dawood

Tanta, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRPF

Identifier Type: -

Identifier Source: org_study_id